Amato, Maria Pia
Bergamaschi, Roberto
Centonze, Diego
Mirabella, Massimiliano
Marfia, Girolama Alessandra
Totaro, Rocco
Lus, Giacomo
Brescia Morra, Vincenzo
Aguglia, Umberto
Comi, Cristoforo
Cavalla, Paola
Zaffaroni, Mauro
Rovaris, Marco
Grimaldi, Luigi Maria
Leoni, Stefania
Malucchi, Simona
Baldi, Eleonora
Romano, Marcello
Falcini, Mario
Perini, Paola
Assetta, Maurizio
Portaccio, Emilio
Sommacal, Sergio
Olivieri, Nunzio
Parodi, Franco
Todaro, Daniele Santo
Grassivaro, Nicoletta
Farina, Alberto http://orcid.org/0000-0003-1896-1179
Mondino, Margaret Mary
Filippi, Massimo
Trojano, Maria
Funding for this research was provided by:
Sanofi
Università degli Studi di Bari Aldo Moro
Article History
Received: 19 April 2023
Revised: 8 June 2023
Accepted: 11 June 2023
First Online: 5 July 2023
Declarations
:
: MPA has served on scientific advisory boards for Biogen, Novartis, Roche, Merck, Sanofi and Teva; has received speaker honoraria from Biogen, Merck, Sanofi, Roche, Novartis and Teva; her Institution has received research grants from Biogen, Merck, Sanofi, Novartis and Roche. She is co-Editor of the Multiple Sclerosis Journal and Associate Editor of Frontiers in Neurology. RB has served on scientific advisory boards for Biogen, Merck-Serono, Novartis, Sanofi; has had travel and congress expenses sustained by Biogen, Bristol Myers Squibb, Janssen, Merck-Serono, Roche, Sanofi; has received honoraria for speaking engagement from Biogen, Bristol Myers Squibb, Janssen, Merck-Serono, Novartis, Sanofi; his Institution has received research grants from Biogen, Merck-Serono, Novartis, Sanofi. MM has received consulting and/or speaking fees, and/or research support from Alexion, Almirall, Biogen, Bristol Myers Squibb, CSL Behring, Janssen, Merck Serono, Mylan, Novartis, Sanofi, Roche, Viatris; he is a principal investigator in clinical trials for Biogen, Merck Serono, Novartis, Roche, Sanofi. GL has received consulting and/or speaking fees, and/or research support from Alexion, Bristol Myers Squibb, Bayer, Biogen, Merck Serono, Novartis, Sanofi, Almirall, Allergan, Merz, Ipsen, Roche. CC has received speaking fees from Sanofi; has had travel expenses sustained by Sanofi. PC has served on scientific advisory boards Sanofi; has had travel and congress expenses sustained by Sanofi; has received honoraria for speaking engagement from Sanofi; her Institution has received research support from Biogen, Merck-Serono, Novartis, Sanofi. MZ in the last two years has served on scientific advisory boards and received honoraria for speaking or support for travel and congress attendance from Alexion, Almirall, Biogen, Janssen, Merck-Serono, Novartis, Roche, Sanofi. EB has had travel and congress expenses sustained by Sanofi; has received honoraria for speaking engagement from Sanofi. MF (22) has had travel and congress expenses sustained by, has served on scientific advisory boards, and/or has received honoraria for speaking engagement from Novartis, Roche, Biogen, Sanofi, Merck. EP has had travel and congress expenses sustained by, has served on scientific advisory boards, and/or has received honoraria for speaking engagement from Biogen, Merck Serono, Sanofi, Teva, Novartis, Celgene and Roche; he serves on the editorial board of Frontiers in Neurology and Brain Sciences. MF (27–31) is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; has received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; has received speaker honoraria from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Sanofi, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and Teva; has served on scientific advisory boards for Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol Myers Squibb, Lilly, Novartis, Sanofi; he receives research support from Biogen, Merck-Serono, Novartis, Roche, Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. MT has served on scientific advisory boards for Biogen, Novartis, Roche, Merck, BMS and Sanofi; has received speaker honoraria from Biogen, Roche, Sanofi, Merck and Novartis; has received research grants for her Institution from Biogen, Merck, Novartis and Roche. SS was a Sanofi employees at the time the work was done. NO, FP, DST, NG, AF, MMM are Sanofi employees.
: The NEDA3PLUS study have been approved by the ethics committee of each participating center and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave their informed consent prior to their inclusion in the study.